Citation | Lewis, RT; Bode, CM; Choquette, DM; Potashman, M; Romero, K; Stellwagen, JC; Teffera, Y; Moore, E; Whittington, DA; Chen, H; Epstein, LF; Emkey, R; Andrews, PS; Yu, VL; Saffran, DC; Xu, M; Drew, A; Merkel, P; Szilvassy, S; Brake, RL The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem55:6523-40 (2012) [PubMed] Article |
---|
SMILES | CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccccc12 |r,wU:9.12,6.5,(31.37,-49.74,;29.87,-49.42,;29.39,-47.96,;28.84,-50.57,;27.33,-50.25,;26.3,-51.4,;26.85,-48.79,;25.34,-48.47,;24.87,-47.01,;25.9,-45.86,;27.4,-46.17,;27.88,-47.64,;25.41,-44.4,;26.32,-43.14,;27.86,-43.13,;28.62,-41.8,;27.84,-40.47,;30.16,-41.79,;30.93,-43.11,;32.47,-43.11,;33.24,-41.77,;34.78,-41.76,;32.45,-40.43,;30.91,-40.45,;25.4,-41.89,;23.93,-42.38,;22.59,-41.62,;21.26,-42.39,;21.26,-43.93,;22.59,-44.7,;23.93,-43.93,)| |